Stock Analysis on Net

Cigna Group (NYSE:CI)

$22.49

This company has been moved to the archive! The financial data has not been updated since February 27, 2025.

Economic Value Added (EVA)

Microsoft Excel

EVA is registered trademark of Stern Stewart.

Economic value added or economic profit is the difference between revenues and costs,where costs include not only expenses, but also cost of capital.

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Economic Profit

Cigna Group, economic profit calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Net operating profit after taxes (NOPAT)1
Cost of capital2
Invested capital3
 
Economic profit4

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 NOPAT. See details »

2 Cost of capital. See details »

3 Invested capital. See details »

4 2024 Calculation
Economic profit = NOPAT – Cost of capital × Invested capital
= × =


Net Operating Profit After Taxes (NOPAT)
The net operating profit after taxes experienced a substantial decline from 9227 million USD in 2020 to 6235 million USD in 2021. Following this, there was a moderate recovery to 7303 million USD in 2022. However, the profit declined again in the subsequent years, reaching 4831 million USD in 2023 and slightly increasing to 4868 million USD in 2024. Overall, the trend indicates volatility and difficulty in sustaining higher profit levels after 2020.
Cost of Capital
The cost of capital showed a gradual increase over the period. It started at 7.66% in 2020 and slightly decreased to 7.58% in 2021. Subsequently, it rose to 8.33% in 2022, then to 8.48% in 2023, before slightly decreasing to 8.33% in 2024. This upward trend suggests a generally rising expense associated with funding the company’s operations, which could impact the overall profitability and investment decisions.
Invested Capital
The invested capital demonstrates a downward trend over the five-year period. Beginning at 93748 million USD in 2020, it declined steadily each year, ending at 81638 million USD in 2024. This reduction in invested capital may reflect divestitures, asset sales, or other strategic capital management decisions, indicating a smaller asset base being employed in the business operations over time.
Economic Profit
Economic profit exhibited considerable fluctuations, starting positively at 2047 million USD in 2020, then turning negative to -643 million USD in 2021. It briefly returned to a positive value of 171 million USD in 2022 but dropped sharply to -2446 million USD in 2023 and remained negative at -1936 million USD in 2024. The persistent negative economic profit in the last two years signals that the company was generating returns below its cost of capital, implying value destruction during that period.

Net Operating Profit after Taxes (NOPAT)

Cigna Group, NOPAT calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Shareholders’ net income
Deferred income tax expense (benefit)1
Increase (decrease) in equity equivalents2
Interest expense on long-term and short-term debt
Interest expense, operating lease liability3
Adjusted interest expense on long-term and short-term debt
Tax benefit of interest expense on long-term and short-term debt4
Adjusted interest expense on long-term and short-term debt, after taxes5
Net income (loss) attributable to noncontrolling interest
Net operating profit after taxes (NOPAT)

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Elimination of deferred tax expense. See details »

2 Addition of increase (decrease) in equity equivalents to shareholders’ net income.

3 2024 Calculation
Interest expense on capitalized operating leases = Operating lease liability × Discount rate
= × =

4 2024 Calculation
Tax benefit of interest expense on long-term and short-term debt = Adjusted interest expense on long-term and short-term debt × Statutory income tax rate
= × 21.00% =

5 Addition of after taxes interest expense to shareholders’ net income.


Shareholders’ Net Income
The shareholders’ net income demonstrates a fluctuating but overall downward trend over the five-year period. Starting at US$ 8,458 million in 2020, it declined significantly in 2021 to US$ 5,365 million. A recovery is observed in 2022, with an increase to US$ 6,668 million, but this is followed by consecutive decreases in 2023 and 2024, reaching US$ 5,164 million and US$ 3,434 million respectively. The decline from 2020 to 2024 amounts to approximately 59%, indicating decreasing profitability returned to shareholders.
Net Operating Profit After Taxes (NOPAT)
NOPAT exhibits a somewhat similar pattern to shareholders’ net income, with a decline from US$ 9,227 million in 2020 to US$ 6,235 million in 2021. It improved moderately in 2022 to US$ 7,303 million, but then experienced a marked drop to US$ 4,831 million in 2023. Contrary to shareholders’ net income, NOPAT shows a slight recovery in 2024, increasing marginally to US$ 4,868 million. Despite the recovery in 2024, NOPAT decreased by roughly 47% when comparing 2020 to 2024, signaling reduced operational efficiency or increased costs impacting the company’s profitability after tax.
Comparative Observations
Both financial indicators show volatility, with notable declines early in the period followed by partial recoveries and subsequent decreases. Shareholders’ net income declined more steeply than NOPAT over the five years, particularly between 2023 and 2024. The divergence in trends for 2023 and 2024, where shareholders’ net income continued falling while NOPAT rebounded slightly, suggests potential impacts from non-operating items, taxes, or other extraordinary factors affecting net income specifically. Overall, the trends point to challenges in maintaining consistent profitability and returns to shareholders over the recent years.

Cash Operating Taxes

Cigna Group, cash operating taxes calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Income taxes
Less: Deferred income tax expense (benefit)
Add: Tax savings from interest expense on long-term and short-term debt
Cash operating taxes

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).


Income Taxes
The income taxes exhibit significant fluctuations over the years. In 2020, the amount stood at 2,379 million US dollars before experiencing a notable decline to 1,367 million in 2021. Subsequently, there was an increase to 1,607 million in 2022, followed by a sharp drop to 141 million in 2023. In 2024, income taxes rose again to 1,491 million. The volatility suggests changes in taxable income, tax planning strategies, or legislative impacts during this period.
Cash Operating Taxes
Cash operating taxes show a downward trend with some fluctuations. Starting at 3,064 million US dollars in 2020, the value fell sharply to 1,864 million in 2021. There was then an increase to 2,363 million in 2022, followed by a decline to 2,097 million in 2023 and further to 1,901 million in 2024. Despite the fluctuations, the overall pattern points towards a reduction in cash tax outflows over the five-year period.
Comparative Analysis
Comparing income taxes and cash operating taxes reveals that cash operating taxes consistently remain higher than income taxes across all years. Both metrics have experienced declines from 2020 to 2021, followed by recoveries in 2022. However, while income taxes sharply fell in 2023 to a very low level, cash operating taxes decreased more moderately that year. The 2024 data indicates a recovery in income taxes to near previous levels, whereas cash operating taxes continued a slight downward trend. This pattern may reflect timing differences between tax accruals and payments, or changes in tax assets and liabilities.

Invested Capital

Cigna Group, invested capital calculation (financing approach)

US$ in millions

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Short-term debt
Long-term debt
Operating lease liability1
Total reported debt & leases
Shareholders’ equity
Net deferred tax (assets) liabilities2
Equity equivalents3
Accumulated other comprehensive (income) loss, net of tax4
Redeemable noncontrolling interests
Other noncontrolling interests
Adjusted shareholders’ equity
Invested capital

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Addition of capitalized operating leases.

2 Elimination of deferred taxes from assets and liabilities. See details »

3 Addition of equity equivalents to shareholders’ equity.

4 Removal of accumulated other comprehensive income.


Total reported debt & leases
The total reported debt and leases showed an overall downward trend from 2020 to 2023, decreasing from 33,562 million US dollars in 2020 to 31,375 million US dollars in 2023. However, in 2024, there was a slight increase to 31,972 million US dollars. This indicates a general reduction in debt levels over the period with a minor reversal in the final year.
Shareholders’ equity
Shareholders’ equity consistently declined over the analyzed period, starting at 50,321 million US dollars in 2020 and decreasing each year to reach 41,033 million US dollars in 2024. This represents a significant reduction, suggesting that the company's net assets or retained earnings diminished over time, which might impact its financial stability and capital structure.
Invested capital
Invested capital exhibited a steady decline from 93,748 million US dollars in 2020 to 81,638 million US dollars in 2024. The decrease was gradual without any abrupt changes, reflecting a possible contraction in the total capital used for business operations. This trend corresponds with the reductions seen in both debt and equity, implying overall scaling down of the company's capital base.

Cost of Capital

Cigna Group, cost of capital calculations

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2024-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2023-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2022-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2021-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2020-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »


Economic Spread Ratio

Cigna Group, economic spread ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in millions)
Economic profit1
Invested capital2
Performance Ratio
Economic spread ratio3
Benchmarks
Economic Spread Ratio, Competitors4
Abbott Laboratories
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Economic profit. See details »

2 Invested capital. See details »

3 2024 Calculation
Economic spread ratio = 100 × Economic profit ÷ Invested capital
= 100 × ÷ =

4 Click competitor name to see calculations.


Economic Profit
The economic profit exhibited significant variability over the five-year period, starting at a positive value of 2,047 million US dollars in 2020. It then declined sharply to a negative figure of 643 million in 2021, followed by a moderate recovery to 171 million in 2022. Subsequently, economic profit deteriorated again to negative values of 2,446 million in 2023 and 1,936 million in 2024. This pattern indicates fluctuating profitability with an overall trend toward substantial economic losses in the most recent years.
Invested Capital
The invested capital showed a downward trend throughout the period. It decreased gradually from 93,748 million US dollars in 2020 to 81,638 million in 2024. The reduction was relatively steady, with moderate declines each year, suggesting a consistent contraction or divestment of the capital base over time.
Economic Spread Ratio
The economic spread ratio followed a similar trend to economic profit, starting positively at 2.18% in 2020, before turning negative at -0.71% in 2021. There was a slight return to positive territory at 0.2% in 2022, but thereafter the ratio decreased sharply into negative values of -2.85% in 2023 and -2.37% in 2024. This indicates declining efficiency in generating returns above the cost of capital, with increasing negative spreads in recent years.

Overall, the data reflect a challenging financial environment characterized by declining invested capital, volatile and generally negative economic profit, and consistently worsening economic spread ratios in the later years. These trends suggest difficulties in maintaining profitability and capital efficiency.


Economic Profit Margin

Cigna Group, economic profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in millions)
Economic profit1
Revenues from external customers
Performance Ratio
Economic profit margin2
Benchmarks
Economic Profit Margin, Competitors3
Abbott Laboratories
Elevance Health Inc.
Intuitive Surgical Inc.
Medtronic PLC
UnitedHealth Group Inc.

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Economic profit. See details »

2 2024 Calculation
Economic profit margin = 100 × Economic profit ÷ Revenues from external customers
= 100 × ÷ =

3 Click competitor name to see calculations.


Revenues from External Customers
There is a consistent upward trend in revenues over the five-year period. Starting at $159,157 million in 2020, revenues increased each year, reaching $246,148 million by 2024. This indicates steady top-line growth and expanding business operations.
Economic Profit
The economic profit shows significant volatility across the years. It started positive at $2,047 million in 2020 but dropped sharply into negative territory in 2021 with a loss of $643 million. A recovery occurred in 2022, albeit modestly positive at $171 million, before declining further into larger losses in 2023 and 2024, reaching -$2,446 million and -$1,936 million respectively. This pattern suggests challenges in generating value above the cost of capital, despite increasing revenues.
Economic Profit Margin
The economic profit margin mirrors the trend in economic profit, reflecting profitability relative to revenues. It began positively at 1.29% in 2020, turned negative in 2021 at -0.37%, recovered to a marginally positive 0.1% in 2022, and then declined again to -1.26% and -0.79% in 2023 and 2024 respectively. The margins confirm persistent profitability pressures and inefficiencies affecting earnings despite revenue growth.
Overall Analysis
The data reveals a paradox of rising revenues coupled with declining economic profitability. While sales have grown substantially, the company has struggled to convert this top-line growth into sustainable economic profit. The recurring negative economic profits and margins from 2021 onward point to increased costs, pricing pressures, or other operational challenges that outweigh the benefits of increased sales. This trend raises concerns about long-term value creation and suggests a need for strategic review to improve profitability and capital efficiency.